The recombinant human ITPRIPL1 protein is an active form expressed in a mammalian system to maintain native folding and post-translational modifications essential for functionality. It consists of amino acids 25 to 103, representing the extracellular region of the human ITPRIPL1 protein, and is fused with a C-terminal 10xHis tag for ease of purification and detection. Supplied as a lyophilized powder, this recombinant ITPRIPL1 protein meets high-quality standards, with purity greater than 95% as confirmed by SDS-PAGE and endotoxin levels kept below 1.0 EU/µg, verified by the LAL assay. Functional ELISA results show that when immobilized at 2 μg/mL, ITPRIPL1 binds specifically to the anti-ITPRIPL1 recombinant antibody (CSB-RA756966MA1HU), with an EC50 ranging from 6.537 to 7.663 ng/mL. This makes it a reliable reagent for antibody validation, molecular interaction studies, and functional assays involving ITPRIPL1.
The human ITPRIPL1 protein has garnered attention for its functional roles in various biological contexts, particularly within immunology and oncology. ITPRIPL1 is a single-pass transmembrane protein that interacts with inositol trisphosphate receptors and influences intracellular calcium signaling pathways integral to numerous cellular processes such as proliferation, differentiation, and apoptosis [1].
Recent research has highlighted the implications of ITPRIPL1 in cancer biology. Specifically, ITPRIPL1 has been characterized as a potential immunological biomarker and prognostic factor in various cancers, including non-small cell lung cancer [1][2]. The expression levels of ITPRIPL1 in the tumor microenvironment are often correlated with the activity of CD8+ T cells. Lower levels of ITPRIPL1 have been associated with increased T cell infiltration, which is critical for effective anti-tumor responses [1]. The reduction of T cell activity linked to ITPRIPL1 expression suggests that this protein may serve as a modulator of immune evasion in tumors, promoting tumor growth through immune suppression mechanisms [1].
It has been suggested that variations in ITPRIPL1 expression impact signaling pathways, particularly the PI3K pathway, which is important in cancer progression and cell survival [1]. The interplay between ITPRIPL1 and these growth factor signaling pathways indicates the protein's participation in regulating cellular homeostasis and response to external signals.
Furthermore, ITPRIPL1 interacts with other proteins that mediate signaling pathways related to cancer progression, including its potential co-existence with proteins such as ANKRD36, which highlights its involvement in complex biological networks associated with tumorigenesis and disease progression [3]. The overall evidence points to ITPRIPL1 acting as an intracellular signaling mediator and a pivotal actor in the immune landscape of tumors, proposing a multifaceted role in cancer biology that warrants further exploration.
References:
[1] W. Duan, W. Tian, Z. Li, Y. Liu, & L. Xu. A comprehensive pan-cancer analysis revealing the role of itpripl1 as a prognostic and immunological biomarker. Frontiers in Molecular Biosciences, vol. 11, 2024. https://doi.org/10.3389/fmolb.2024.1452290
[2] S. Deng, J. Shi, et al. Development of a monoclonal antibody to itpripl1 for immunohistochemical diagnosis of non-small cell lung cancers: accuracy and correlation with cd8+ t cell infiltration. Frontiers in Cell and Developmental Biology, vol. 11, 2023. https://doi.org/10.3389/fcell.2023.1297211
[3] Z. Iqbal, M. Absar, et al. Integrated genomic analysis identifies ankrd36 gene as a novel and common biomarker of disease progression in chronic myeloid leukemia. 2021. https://doi.org/10.20944/preprints202108.0498.v1
